Drug-drug interactions and the pharmacotherapy of HIV infection

Abstract

Knowledge of drug-drug interactions is crucial to HIV therapeutics. Recent reports in this area include reduced atazanavir exposure with coadministration of omeprazole or rifampin; increased hepatic toxicity with coadministration of saquinavir and rifampin; reduced buprenorphine exposure with concurrent efavirenz administration; absence of clinically significant interactions of depomedroxyprogesterone with nevirapine, efavirenz, or nelfinavir; increased atazanavir and saquinavir exposure with the double-boosted regimen of atazanavir/saquinavir/ritonavir; reduced amprenavir, lopinavir, and saquinavir exposure with the addition of tipranavir/ritonavir therapy; and reduced lopinavir and amprenavir exposure with the addition of fosamprenavir or fosamprenavir/ritonavir to lopinavir/ritonavir. This article summarizes a presentation on drug-drug interactions in HIV therapeutics by Angela D. M. Kashuba, PharmD, at the International AIDS Society-USA course in Los Angeles in April 2005.